Clinical Trials Browser

Phase 1/2 × OTHER × Disulfides × Clear all

NCT04902040 2026-04-30

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT03942328 2026-04-20

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Phase 1/2 Recruiting

85 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT01684397 2026-02-27

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Phase 1/2 Active not recruiting

51 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

Phase 1/2 Active not recruiting

47 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

NCT02726997 2025-12-18

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Phase 1/2 Active not recruiting

18 enrolled

Gynecologic

Fallopian Tube Neoplasms

NCT04728230 2025-12-18

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

Phase 1/2 Active not recruiting

63 enrolled

Thoracic

Lung Neoplasms

NCT05455697 2025-12-18

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Phase 1/2 Recruiting

35 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05627635 2025-11-10

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

20 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase 1/2 Completed

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03011814 2025-09-18

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Phase 1/2 Active not recruiting

38 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT06543576 2025-08-15

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

Phase 1/2 Recruiting

35 enrolled

Gynecologic

Cervical Adenocarcinoma

NCT04019288 2025-06-11

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1/2 Terminated

12 enrolled 13 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05191797 2024-09-26

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Phase 1/2 Terminated

3 enrolled 8 charts

Extensive Stage Lung Small Cell Carcinoma

NCT04676087 2024-08-13

Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

Phase 1/2 Terminated

5 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT02581787 2024-03-27

SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

Phase 1/2 Completed

28 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03618134 2023-11-18

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Phase 1/2 Terminated

19 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT03522584 2023-06-12

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Terminated

6 enrolled 8 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck